Industry-Sponsored Product Theaters

12:05 PM – 1:05 PM ET

The Therapeutic Transformation of Bladder Cancer: Understanding Immune, Targeted, and Antibody-Based Models for Patient Care

Matthew D. Galsky, MD
Sponsored by PeerView

Post-Test and CME Evaluation >>

1:05 PM – 1:45 PM ET

Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer: Rationale, Evidence, and Clinical Implications

Emmanuel S. Antonarakis, MD
Sponsored by PeerView

Post-Test and CME Evaluation >>


Indian American Urological Association
2021 IAUA Young Clinicians Forum
May 1, 2021
Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion.  Your chosen sessions must be attended in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.


Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and North American Robotic Urology Symposium (NARUS).  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Objectives – After Attending This Program You Should Be Able To

  1. Determine best treatment candidates for surgical treatment of overactive bladder.
  2. Determine the right patients for cytoreductive nephrectomy for kidney cancer.
  3. Discuss shared-decision making for men with metastatic prostate cancer.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed in the agenda. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

First Last Commercial Interest
Sanoj Punnen ExosomeDx:Speakers Bureau,Decipher:Speakers Bureau
Vignesh Packiam Cold Genesys:Consultant
Rena Malik Urovant Sciences:Consultant
Anand Shridharani Coloplast:Consultant
R Ramasamy Direx :Research Grant Site Principal Investigator,Aytu Biosciences:Research Grant Site Principal Investigator,Aytu Biosciences:Consultant,Coloplast:Consultant,Acerus Pharmaceuticals:Consultant,Boston Scientific:Consultant,Boston Scientific:Research Grant Site Principal Investigator,Coloplast:Research Grant Site Principal Investigator,Endo Pharmaceuticals:Research Grant Site Principal Investigator,Endo Pharmaceuticals:Consultant,Nestle Health:Consultant

How to Get Your Certificate

  1. Go to
  2. Click on the “2021 Virtual Young Clinicians Forum” link.
  3. Evaluate the meeting.
  4. Print all pages of your certificate for your records.

    Questions? Email


    Interested in sponsoring the IAUA 2021 Young Clinicians Forum?  Download the Partnership Prospectus by clicking the image below or contact Denise Castetter at

    Gold Sponsor